Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Commvault Systems Inc (CVLT) vs GeneDx Holdings Corp (WGS) Price & Performance

Commvault Systems IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Commvault Systems Inc vs GeneDx Holdings Corp — how do they compare? Commvault Systems Inc trades at $150.08 (market cap $6.15B), while GeneDx Holdings Corp trades at $63.18 (market cap $1.85B). The key difference: Commvault Systems Inc is far larger — about 3.3× GeneDx Holdings Corp's market cap, and Commvault Systems Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

CVLTWGS
Market Cap
$6.15B$1.85B
Sector
TechnologyTechnology
52-Week High
$195.41$167.51
52-Week Low
$75.18$34.51
Enterprise Value
$6.17B$1.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Commvault Systems Inc

Commvault (CVLT) trades at $148.65, down 1.28% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.09 estimate, though Q3 2025 missed expectations. Revenue reached $995.62 million in 2025, with a net income margin of 5.97%. However, valuation ratios are elevated, including a P/E of 94.03 and P/B of 821.14, indicating high growth expectations. Recent news highlights multiple class-action lawsuits with a July 17, 2026 deadline, adding legal overhangs.

The outlook for CVLT is mixed, with solid profitability and analyst buy ratings (54.55% consensus) supporting upside to the $155.00 high target, but risks from the lawsuits and rich valuations could pressure the stock. Investors should weigh robust cash flow growth in 2026 against potential legal and competitive headwinds in the data protection sector.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $63.85, down 2.73% amid multiple securities class action lawsuits alleging misleading acquisition performance disclosures. The stock shows bearish technical signals with support at $60 and resistance at $65. Fundamentally, the company reported negative net income of -$21.02M for 2025 despite revenue growth to $427.54M, with profitability metrics deteriorating significantly in 2026 projections.

Despite 91% analyst buy ratings and a $75.40 consensus target, substantial legal risks and negative earnings momentum create significant headwinds. The stock faces near-term pressure from litigation while long-term viability depends on reversing negative margin trends and resolving acquisition-related impairment issues that triggered the 49% stock decline cited in lawsuits.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS